Latest Revenue Guidance News

SKS Technologies has landed its largest data centre contract yet, a $130 million project in Melbourne, lifting its total work on hand to $304 million and prompting an upward revision of its FY26 revenue guidance.

Acusensus Limited has raised its FY26 revenue guidance to $83-$87 million, driven by significant new contracts in the US and New Zealand and expansions in Australia. This upgrade signals strong momentum in the company’s AI-powered road safety enforcement business.

Lycopodium Limited projects steady growth for FY26 with revenue guidance of $390-$410 million, underpinned by strong project momentum and the strategic SAXUM acquisition expanding its footprint in the Americas.

Life360 has reported a record-breaking third quarter in 2025, with significant growth in users, revenue, and profitability, while announcing a strategic acquisition to expand its advertising capabilities.

Etherstack plc reports a record-breaking FY25 with revenues up 62%, driven by major US and UK contracts, and projects continued strong growth into FY26 and beyond.

Monadelphous Group Limited has raised its revenue guidance for 2025, buoyed by strong contract awards and elevated activity across its engineering and construction divisions.

Etherstack’s subsidiary has landed a A$2.5 million contract with the Australian Defence, reinforcing its growing footprint in sovereign defence communications.

AVITA Medical reported a 13% drop in Q3 commercial revenue to $17.1 million but improved its net loss and secured CE Mark approval for RECELL GO in Europe, signaling strategic shifts ahead.

oOh!media reports a 7% revenue increase in Q3 2025, slightly ahead of prior guidance, but flags challenges from a key New Zealand contract loss and softer advertising demand in October.

Nova Eye Medical reported a 20% year-on-year revenue increase in Q1 FY26, reaffirming its FY26 sales guidance and targeting breakeven EBITDA by June 2026 amid cautious commercial expansion.

Austin Engineering has lowered its FY26 revenue and EBIT forecasts due to challenges in key contracts and operational inefficiencies, while outlining strategic measures to restore profitability.

Bioxyne Limited, through its subsidiary Breathe Life Sciences, has inked an exclusive deal to import, manufacture, and distribute Curaleaf’s Que Medical Inhalation Device in Australia, with a nationwide launch set for November 2025.